Corrigendum: Development of phage cocktails to treat E. coli catheter-associated urinary tract infection and associated biofilms

Front Microbiol. 2022 Aug 9:13:953136. doi: 10.3389/fmicb.2022.953136. eCollection 2022.

¹ Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States.
² Department of Microbiology and Molecular Genetics, McGovern Medical School, UTHealth Houston, Houston, TX, United States.
³ Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
⁴ Pathology and Laboratory Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
⁵ Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
⁶ Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
⁷ H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX, United States.
⁸ Department of Medicine and Surgery, Baylor College of Medicine, Houston, TX, United States.
⁹ Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, TX, United States.

Abstract

[This corrects the article DOI: 10.3389/fmicb.2022.796132.].

Keywords: CAUTI; biofilms; multidrug-resistance; phage therapy; uropathogenic E. coli.